` 460 (Sihuan Pharmaceutical Holdings Group Ltd) vs Hang Seng (Hong Kong) Comparison - Alpha Spread
Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in

460
vs
H
Hang Seng (Hong Kong)

Over the past 12 months, Sihuan Pharmaceutical Holdings Group Ltd has significantly outperformed Hang Seng (Hong Kong), delivering a return of +165% compared to the Hang Seng (Hong Kong)'s +13% growth.

Back to 460 Analysis

Stocks Performance
460 vs Hang Seng (Hong Kong)

Loading
460
Hang Seng (Hong Kong)
Add Stock
www.alphaspread.com
1Y 3Y 5Y 10Y 15Y 20Y
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
460 vs Hang Seng (Hong Kong)

Loading
460
Hang Seng (Hong Kong)
Difference
www.alphaspread.com
1Y 3Y 5Y 10Y 15Y 20Y

Performance By Year
460 vs Hang Seng (Hong Kong)

Loading
460
Hang Seng (Hong Kong)
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Sihuan Pharmaceutical Holdings Group Ltd vs Peers

Hang Seng (Hong Kong)
460
JEF
JNJ
4312
Add Stock
1Y 3Y 5Y 10Y 15Y 20Y
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Sihuan Pharmaceutical Holdings Group Ltd
Glance View

Market Cap
15.1B HKD
Industry
Pharmaceuticals

Sihuan Pharmaceutical Holdings Group Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products. The company is headquartered in Beijing, Beijing and currently employs 4,282 full-time employees. The company went IPO on 2010-10-28. The firm is mainly engaged in the research and development, manufacture and sales of pharmaceutical products in China. Its products are applicable in cardio-cerebral vascular (CCV) system, central nervous system, metabolism, oncology and anti-infective fields. Its CCV products include Kelinao, Anjieli and Oudimei, among others. Its non-CCV products include Ren’Ao, Metronidazole and Clindamycin, among others.

Intrinsic Value
0.5 HKD
Overvaluation 70%
Intrinsic Value
Price
What is Intrinsic Value?
Back to Top
ALPHA SPREAD
Follow us
Join more than 319,300+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.